Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials? is a research paper published in Current Hematologic Malignancy Reports (2019). On theSindex it has a DataRank of 1.5. It has been cited 29 times, with 24 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.510
From this paper's citation signal
Citation Network Contribution
0.987
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 24 citers.
NCI NIH HHS
Grant: P30 CA016056
FWCI
2.09
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords